vaccine adjuvant raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-03 and is reviewed periodically as new material appears.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
=== Deactivation === The bioactivity of calcitriol is terminated by hydroxylation at position 24 by vitamin D3 24-hydroxylase, coded for by gene CYP24A1, forming calcitetrol. Further metabolism yields calcitroic acid, an inactive water-soluble compound that is excreted in bile. Vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol) share a similar but not identical mechanism of action. Metabolites produced by vitamin D2 are named with an er- or ergo- prefix to differentiate them from the D3-based counterparts (sometimes with a chole- prefix).
== Medical uses == Uses include for fungal infections of the foot, impetigo, pemphigus, superficial wounds, dermatitis (eczema), and tropical ulcers. Typically it is used in skin conditions that produce a lot of liquid. For tropical ulcers it is used together with procaine benzylpenicillin for two to four weeks. It can be used in children and adults. It can be applied as a soaked dressing or a bath. Petroleum jelly may be used on the nails before soaking to prevent their discoloration. The U.S. Food and Drug Administration does not recommend its use in either the crystal or tablet form.
=== Design === Some teams are developing interoperable solutions, but this is not common. Governments express concerns over data sovereignty. WHO established a "working group focused on establishing standards for a common architecture for a digital smart vaccination certificate to support vaccine(s) against COVID-19 and other immunizations". The COVID-19 Credentials Initiative hosted by Linux Foundation Public Health (LFPH) is a global initiative working to develop and deploy privacy-preserving, tamper-evident and verifiable credential certification projects based on the open standard Verifiable Credentials (VCs).
Studies of food processing impact on public health and other outcomes, such as affordability, energy efficiency, food safety and sustainability benefit from the use of FPL. Several food ingredients, which have different FPL, are often used in food products. The highest FPL used to obtain ingredients for intermittent processing of formulated foods and the FPL of final processing, whichever is the highest, indicates the FPL of the final food. Final food products may be formulated using ingredients from several FPL which, when including ingredients or processing at FPL 3 and 4, are assigned to the highest FPL 4.
The ring destructive pathway consists of the selective cleavage of carbon-carbon bonds with release of small organic sulfides soluble in the surrounding aqueous environment, whereas the sulfur-specific pathways rely on successive sulfur redox reactions to release sulfur either as sulfide or sulfite anions as byproducts. The latter have thus been considered as a very promising pathway to produce sulfur-free compounds with a high calorific content, in particular in the desulfurization of sulfur heterocycles abundant in sour crude oil fractions.
Sources: en.wikipedia.org
In series 4, Eric is retired, wealthy but professionally adrift and estranged from his children, when Harper recruits him to co-found SternTao, a fund dedicated to shorting corrupt companies, with fintech firm Tender as their first major target. Eric liquidates his family office to finance the venture, and he and Harper clash over boundaries, with Harper accusing him of losing his edge and using the partnership to compensate for his failures as a father. Eric identifies Tender’s “satellite office” in Sunderland, prompting Harper’s investigation into the company’s laundering of African revenues. He later receives a secretly recorded video of himself with a prostitute named Dolly—planted by Tender—alongside a passport indicating she is 15 years old. Despite the blackmail, Eric appears on CNN opposite Whitney Halberstram to call for a new audit. He then abruptly dissolves SternTao and ends his partnership with Harper without explanation; Harper brands him a coward. The Tender short ultimately nets £110 million, but Eric does not answer when Harper calls to share the news. Yasmin later shows Harper the incriminating video, falsely claiming Dolly misrepresented her age and that Eric was attracted to the idea of sleeping with a teenager, further devastating Harper.
Significant increases in central MP levels were also observed after just two weeks of supplementation. Furthermore, in patients who had an atypical MP distribution in the eye (i.e., they did not have a high concentration of pigment in the centre of the macula), when supplemented with a meso-zeaxanthin-dominant supplement for 8 weeks, the normal pigment profile was reinstated, whereas this was not the case when patients were supplemented with a formulation lacking meso-zeaxanthin. The main findings from the MOST trials in patients with AMD were published in 2013 and 2015. The series of publications from these trials concluded, "Augmentation of the MP optical density across its spatial profile and enhancements in contrast sensitivity were best achieved after supplementation with a formulation containing high doses of meso-zeaxanthin in combination with lutein and zeaxanthin". Also, the final publication from this work, published in 2015, concluded that, "The inclusion of meso-zeaxanthin in a supplement formulation seems to confer benefits in terms of MP augmentation and in terms of enhanced contrast sensitivity in subjects with early AMD.". In 2016 and 2017, the results of two small clinical trials were published. The first trial, the CREST (Central Retinal Enrichment Supplementation Trials) study involved 105 normal healthy volunteers who underwent a series of complex tests of vision and were supplemented over 12 months.
== Products == There are thought to be a number of useful products that can potentially be manufactured in space and result in an economic benefit. Research and development is required to determine the best commodities to be produced, and to find efficient production methods. The following products are considered prospective early candidates:
==== Nations ==== India: Randhir Jaiswal, the official spokesperson of the Ministry of External Affairs, expressed strong condemnation of the strikes and expressed support for Afghanistan's sovereignty and territorial integrity. Qatar: Qatari foreign minister Mohammed bin Abdulaziz Al Khulaifi discussed with Pakistani Foreign Minister Muhammad Ishaq Dar ways to reduce tension between Pakistan and Afghanistan, thereby strengthening security and stability in the region. Russia: The Russian government offered to mediate the situation and urged both nations to halt cross-border attacks. Saudi Arabia: Prince Faisal bin Farhan and officials in the Pakistani government discussed ways to reduce regional tensions during a phone call. United States: The White House stated that it will continue to monitor the situation closely and expressed support for Pakistan against the Taliban attacks. US president Donald Trump praised both Shehbaz Sharif and Asim Munir for fighting against Taliban forces. In addition, Bangladesh, China, Egypt, Iran, Iraq, Jordan, Malaysia, and Uzbekistan also called for a ceasefire to end hostilities and promoted dialogue to resolve border tensions.
Sources: en.wikipedia.org
=== Efficacy of medication and psychotherapy === Antidepressants are statistically superior to placebo but their overall effect is low-to-moderate. In that respect they often did not exceed the National Institute for Health and Clinical Excellence criteria for a "clinically significant" effect. In particular, the effect size was very small for moderate depression but increased with severity, reaching "clinical significance" for very severe depression. These results were consistent with the earlier clinical studies in which only patients with severe depression benefited from either psychotherapy or treatment with an antidepressant, imipramine, more than from the placebo treatment. Despite obtaining similar results, the authors argued about their interpretation. One author concluded that there "seems little evidence to support the prescription of antidepressant medication to any but the most severely depressed patients, unless alternative treatments have failed to provide benefit." The other author agreed that "antidepressant 'glass' is far from full" but disagreed "that it is completely empty". He pointed out that the first-line alternative to medication is psychotherapy, which does not have superior efficacy. Antidepressants in general are as effective as psychotherapy for major depression, and this conclusion holds true for both severe and mild forms of MDD. In contrast, medication gives better results for dysthymia. The subgroup of SSRIs may be slightly more efficacious than psychotherapy.
== Career == Atul Malhotra, who has more than 25 years of professional experience, is currently the director of research for pulmonary, critical care, and sleep medicine at the University of California, San Diego. He served as a professor of medicine, a sleep medicine specialist, the head of the division for pulmonary and critical care, and the Kenneth Moser Professor during his time at the University of California, San Diego.
=== Medications === The antifibrotics pirfenidone and nintedanib have been shown to slow the decline in lung function (as measured by forced vital capacity [FVC]) in those with ILD compared to placebo. Pirfenidone was associated with a 45% less decline in FVC at 52 weeks compared to placebo in a trial involving people with idiopathic pulmonary fibrosis, and was associated with a slower FVC decline in those with progressive pulmonary fibrosis. Nintedanib was also associated with a slower FVC decline and increased mean survival in people with ILD. The immunomodulator tocilizumab has a benefit in scleroderma associated ILD by helping to preserve lung function (as measured by FVC) at 48 weeks. The immunomodulators cyclophosphamide, mycophenolate mofetil and rituximab all showed improved lung function (as measured by % predicted FVC) compared to placebo in systemic sclerosis or scleroderma associated ILD. The inhaled vasodilator treprostinil (a synthetic prostacyclin which acts as a prostaglandin I2 analogue) is indicated in the treatment of pulmonary hypertension secondary to interstitial lung disease and is associated with improved exercise capacity as measured by a 6-minute walk test.
== History == In 1943, diphenhydramine was discovered by chemist George Rieveschl and one of his students, Fred Huber, while they were conducting research into muscle relaxants at the University of Cincinnati. Huber first synthesized diphenhydramine. Rieveschl then worked with Parke-Davis to test the compound, and the company licensed the patent from him. In 1946, it became the first prescription antihistamine in the United States approved by the FDA. In the 1960s, diphenhydramine was found to weakly inhibit reuptake of the neurotransmitter serotonin. This discovery led to a search for viable antidepressants with similar structures and fewer side effects, culminating in the invention of fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). A similar search had previously led to the synthesis of the first SSRI, zimelidine, from brompheniramine, also an antihistamine. In 1975, diphenhydramine was still available only by prescription in the US and required medical supervision.
Fire was used by the Lower Paleolithic hominins Homo erectus and Homo ergaster as early as 300,000 to 1.5 million years ago and possibly even earlier by the early Lower Paleolithic (Oldowan) hominin Homo habilis or by robust Australopithecines such as Paranthropus. However, the use of fire only became common in the societies of the following Middle Stone Age and Middle Paleolithic. Use of fire reduced mortality rates and provided protection against predators. Early hominins may have begun to cook their food as early as the Lower Paleolithic (c. 1.9 million years ago) or at the latest in the early Middle Paleolithic (c. 250,000 years ago). Some scientists have hypothesized that hominins began cooking food to defrost frozen meat, which would help ensure their survival in cold regions. Archaeologists cite morphological shifts in cranial anatomy as evidence for emergence of cooking and food processing technologies. These morphological changes include decreases in molar and jaw size, thinner tooth enamel, and decrease in gut volume. During much of the Pleistocene epoch, our ancestors relied on simple food processing techniques such as roasting. The Upper Palaeolithic saw the emergence of boiling, an advance in food processing technology which rendered plant foods more digestible, decreased their toxicity, and maximised their nutritional value. Thermally altered rock (heated stones) are easily identifiable in the archaeological record.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.